![](/img/cover-not-exists.png)
1148PACCURACY a phase (P) II trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notch act mut): Preliminary safety and efficacy data
Ferrarotto, R, Ho, A, Wirth, L J, Muzaffar, J, Rodriguez, C, Dekel, E, Walker, R M, Nadri-Shay, C, Vergara-Silva, AVolume:
30
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz252.040
Date:
October, 2019
File:
PDF, 105 KB
english, 2019